Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ashwagandha + liposomal doxorubicin
- Development stage
- Unknown
- Lead developer
- University of Louisville
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Ashwagandha (Withania somnifera) is a natural product being investigated for its anti-cancer properties, primarily through its bioactive compound Withaferin A (WFA). In a Phase 1/2 clinical trial led by Sham Sunder Kakar at the University of Louisville, oral Ashwagandha is being evaluated in combination with liposomal doxorubicin (Doxil) for the treatment of recurrent ovarian cancer, fallopian tube cancer, and primary peritoneal carcinoma. Preclinical evidence suggests that Withaferin A targets and reduces cancer stem cell populations, potentially enhancing the efficacy of standard chemotherapy and overcoming resistance. The combination therapy aims to determine the maximum tolerated dose and feasibility of adding Ashwagandha to a standard liposomal doxorubicin regimen.
- Brand names
- Doxil
- Other names
- Withaferin AWithania somniferaliposomal doxorubicinashwagandha
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on ashwagandha + liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ashwagandha + liposomal doxorubicin.